TriSalus Life Sciences Highlights Clinical Data From Phase 1B Perio-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 Asco Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.